Myelodysplastic Syndrome and Histone Deacetylase Inhibitors: “To Be or Not to Be Acetylated”?

Myelodysplastic syndrome (MDS) represents a heterogeneous group of diseases with clonal proliferation, bone marrow failure and increasing risk of transformation into an acute myeloid leukaemia. Structured guidelines are developed for selective therapy based on prognostic subgroups, age, and performa...

Descripción completa

Detalles Bibliográficos
Autores principales: Stintzing, Sebastian, Kemmerling, Ralf, Kiesslich, Tobias, Alinger, Beate, Ocker, Matthias, Neureiter, Daniel
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2011
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3100562/
https://www.ncbi.nlm.nih.gov/pubmed/21629744
http://dx.doi.org/10.1155/2011/214143

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3100562/
https://www.ncbi.nlm.nih.gov/pubmed/21629744
http://dx.doi.org/10.1155/2011/214143

Ejemplares similares